Azalea Therapeutics, a spinout from Jennifer Doudna’s lab, launched with an $82 million financing to pursue in‑body genome editing approaches that aim to convert patients’ immune cells into CAR‑T‑like effectors with a single infusion. The company plans a dual‑vector strategy and says the investment will accelerate preclinical development of its in‑vivo cell programming platform. In‑vivo CAR‑T refers to technologies designed to reprogram immune cells inside the patient rather than ex vivo manufacturing. Azalea’s fundraise draws on broad investor appetite for technologies that could make cellular immunotherapy faster and cheaper to deliver.